Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Next Previous
Trial Profile

A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms CAROLINA
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 19 May 2023 Results of pre-specified and post-hoc analyses, we investigated treatment effects on total hypoglycaemic burden in CAROLINA, published in the Diabetes, Obesity and Metabolism
  • 07 Nov 2022 Results assessing the associations between hypoglycemia and cardiovascular outcomes from the CARMELINA and CAROLINA trials of the linagliptin, an antihyperglycemic medication, presented at the American Heart Association Scientific Sessions 2022.
  • 01 Feb 2022 Results (n=3163) published in the Nutrition, Metabolism and Cardiovascular Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top